Skip to content

News Releases

 
News Releases
  Date Title and Summary View
Jan 17, 2001
--NEW YORK STOCK EXCHANGE--Ringing the opening bell at the NYSE to celebrate the 12th anniversary of Johnson & Johnson-Merck Consumer Pharmaceuticals Co. and the launch of new Pepcid® Complete, the first and only fast and long-lasting heartburn remedy, will be Peter K. Miller, President of Johnson & Johnson-Merck Con...
Jan 17, 2001
NEW BRUNSWICK, N.J., Jan. 17 -- Johnson & Johnson will host a meeting with investment analysts at 8:30 a.m. on Tuesday, January 23, 2001 in New York to discuss its fourth-quarter earnings. The meeting will be hosted by Ralph S. Larsen, Chairman and Chief Executive Officer. A simultaneous webcast of the meeting for interested investors and othe...
Jan 16, 2001
WHAT: Sizzlin' On The Street with Pepcid Complete and Chile Pepper Magazine -- a day of fiery foods, cool competition and blazing activities to celebrate the launch of new Pepcid® Complete, the first fast and long-lasting heartburn remedy. Attende...
Jan 4, 2001
NEW BRUNSWICK, N.J., Jan. 4 -- Johnson & Johnson (NYSE: JNJ) announced today that its subsidiary, Centocor, Inc., has exercised its option to redeem its 4.75% Convertible Subordinated Debentures due 2005. The redemption date for these Debentures will be February 21, 2001. The redemption price for the Debentures will be equal to 102.714% of t...
Dec 27, 2000
NEW BRUNSWICK, N.J., Dec. 27 -- Johnson & Johnson today reported that its Cordis unit, a leader in circulatory disease management, completed the acquisition of Atrionix, Inc. in an all-cash transaction valued at $62.8 million. Atrionix, a privately held company located in Palo Alto, CA is developing a proprietary, catheter-based system for the trea...
Dec 15, 2000
NEW BRUNSWICK, N.J., Dec. 15-- LifeScan, Inc., a Johnson & Johnson (NYSE: JNJ) company, today entered a plea of guilty to three misdemeanor charges relating to a federal government investigation of its SURESTEP Blood Glucose Meter. LifeScan will pay a fine of $29.4 million and an additional $30.6 million in civil settlement to the government. ...
Dec 15, 2000
NEW BRUNSWICK, N.J., Dec. 15 -- Johnson & Johnson (NYSE: JNJ) announced today that it remains comfortable with guidance as conveyed during its third quarter conference call. During the third quarter conference call, Johnson & Johnson expressed comfort toward or at, but not exceeding the upper end of the range of earnings per share (EPS) estimates a...
Nov 13, 2000
NEW BRUNSWICK, N.J., Nov. 13 -- Johnson & Johnson today announced that it will participate in the Merrill Lynch Medical Technology Fundamentals Conference at the Metropolitan Club in New York City on November 16th and 17th. Company management will be participating in panels on orthopaedics, diagnostics and cardiology. For more information o...
Nov 6, 2000
MIAMI, Nov. 6 -- Cordis Corporation -- the Johnson & Johnson company that pioneered the cardiovascular stent -- received U.S. Food and Drug Administration approval on Friday to market the CHECKMATE(TM) System, an intravascular brachytherapy (radiation) system for recurrent blockages in coronary arteries previously treated with coronary artery stent...
Nov 6, 2000
Until now, no development has been able to overcome the obstacle of recurrent blockages, in treated coronary artery lesions. Cordis Corporation -- the Johnson & Johnson company that pioneered the cardiovascular stent -- announced U.S. Food and Drug Administration (FDA) approval to market the CHECKMATE(TM) System, the first intravascular brachythera...
Page: FirstPrevious ...
164
... NextLast
= add release to Briefcase